Borella Fulvio, Fucina Stefano, Seminara Ylenia, Denti Pietro, Ferraioli Domenico, Bertero Luca, Gallio Niccolò, Cusato Jessica, Valabrega Giorgio, Revelli Alberto, Marozio Luca, Cosma Stefano
Gynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.
Department of Gynecology, Léon Bérard, Comprehensive Cancer Centre, 69008 Lyon, France.
Curr Oncol. 2024 Dec 20;31(12):8054-8074. doi: 10.3390/curroncol31120594.
The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.
拓扑异构酶IIα（TOP2A）在DNA复制和细胞增殖中起着关键作用，使其成为癌症治疗的一个有前景的靶点。在上皮性卵巢癌（EOC）中，TOP2A过表达与预后不良和对传统治疗的耐药性相关。本综述探讨了TOP2A在EOC中的生物学功能，并讨论了其作为治疗靶点的潜力。我们重点介绍了关于TOP2A促进肿瘤进展和复发机制的研究。此外，我们评估了靶向TOP2A的临床意义，包括TOP2A抑制剂的使用及其与新药的联合应用。我们全面概述了目前在EOC治疗中靶向TOP2A的认识和未来方向。
